Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial.
Antibiotics
Antiviral
Complications
Echinacea
Prevention
Respiratory tract infections
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
08 Apr 2021
08 Apr 2021
Historique:
received:
12
11
2020
accepted:
12
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
23
11
2021
Statut:
epublish
Résumé
In children, up to 30% of viral respiratory tract infections (RTIs) develop into bacterial complications associated with pneumonia, sinusitis or otitis media to trigger a tremendous need for antibiotics. This study investigated the efficacy of Echinacea for the prevention of viral RTIs, for the prevention of secondary bacterial complications and for reducing rates of antibiotic prescriptions in children. Echinaforce® Junior tablets [400 mg freshly harvested Echinacea purpurea alcoholic extract] or vitamin C [50 mg] as control were given three times daily for prevention to children 4-12 years. Two × 2 months of prevention were separated by a 1-week treatment break. Parents assessed respiratory symptoms in children via e-diaries and collected nasopharyngeal secretions for screening of respiratory pathogens (Allplex® RT-PCR). Overall, 429 cold days occurred in N Our results support the use of Echinacea for the prevention of RTIs and reduction of associated antibiotic usage in children. Trial registration clinicaltrials.gov, NCT02971384, 23th Nov 2016.
Sections du résumé
BACKGROUND
BACKGROUND
In children, up to 30% of viral respiratory tract infections (RTIs) develop into bacterial complications associated with pneumonia, sinusitis or otitis media to trigger a tremendous need for antibiotics. This study investigated the efficacy of Echinacea for the prevention of viral RTIs, for the prevention of secondary bacterial complications and for reducing rates of antibiotic prescriptions in children.
METHODS
METHODS
Echinaforce® Junior tablets [400 mg freshly harvested Echinacea purpurea alcoholic extract] or vitamin C [50 mg] as control were given three times daily for prevention to children 4-12 years. Two × 2 months of prevention were separated by a 1-week treatment break. Parents assessed respiratory symptoms in children via e-diaries and collected nasopharyngeal secretions for screening of respiratory pathogens (Allplex® RT-PCR).
RESULTS
RESULTS
Overall, 429 cold days occurred in N
CONCLUSIONS
CONCLUSIONS
Our results support the use of Echinacea for the prevention of RTIs and reduction of associated antibiotic usage in children. Trial registration clinicaltrials.gov, NCT02971384, 23th Nov 2016.
Identifiants
pubmed: 33832544
doi: 10.1186/s40001-021-00499-6
pii: 10.1186/s40001-021-00499-6
pmc: PMC8028575
doi:
Substances chimiques
Anti-Bacterial Agents
0
Plant Extracts
0
Banques de données
ClinicalTrials.gov
['NCT02971384']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Références
Arch Pediatr Adolesc Med. 1998 Mar;152(3):244-8
pubmed: 9529461
Pediatr Res. 2010 Sep;68(3):252-7
pubmed: 20520584
BMJ Open. 2017 Nov 15;7(11):e016221
pubmed: 29146635
FEBS Lett. 2004 Nov 19;577(3):563-9
pubmed: 15556647
Arch Pediatr Adolesc Med. 2004 Mar;158(3):217-21
pubmed: 14993078
BMJ. 2007 Nov 10;335(7627):982
pubmed: 17947744
Int J Antimicrob Agents. 2013 Mar;41(3):203-12
pubmed: 23127482
Br J Gen Pract. 2006 Mar;56(524):183-90
pubmed: 16536958
Evid Based Complement Alternat Med. 2012;2012:841315
pubmed: 23024696
J Clin Pharm Ther. 2009 Aug;34(4):387-95
pubmed: 19583671
J Virol. 2008 Mar;82(5):2040-55
pubmed: 17928346
Pediatr Infect Dis J. 2006 Sep;25(9):795-800
pubmed: 16940836
Front Cell Infect Microbiol. 2017 Aug 16;7:367
pubmed: 28861397
Cochrane Database Syst Rev. 2014 Feb 20;(2):CD000530
pubmed: 24554461
BMJ. 2016 Jul 05;354:i3482
pubmed: 27381415
Forsch Komplementarmed Klass Naturheilkd. 2000 Dec;7(6):294-300
pubmed: 11155023
Pediatr Allergy Immunol. 2008 Sep;19(6):505-12
pubmed: 18167154
J Antimicrob Chemother. 2017 Nov 1;72(11):3205-3212
pubmed: 28961815
Cochrane Database Syst Rev. 2013 Aug 08;(8):CD005532
pubmed: 23925826
JAMA. 2003 Dec 3;290(21):2824-30
pubmed: 14657066
Gesundheitswesen. 2005 Apr;67(4):296-301
pubmed: 15856390
Clin Ther. 2002 Jan;24(1):170-82
pubmed: 11833830
Adv Ther. 2015 Mar;32(3):187-200
pubmed: 25784510
Antiviral Res. 2009 Aug;83(2):165-70
pubmed: 19409931
Am J Pathol. 2015 Jun;185(6):1528-36
pubmed: 25747532
AMA Arch Intern Med. 1958 Feb;101(2):267-78
pubmed: 13497324
Virol J. 2009 Nov 13;6:197
pubmed: 19912623
BMC Infect Dis. 2013 Jan 25;13:41
pubmed: 23351117
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000980
pubmed: 23440782
Virol J. 2020 Sep 9;17(1):136
pubmed: 32907596
Mayo Clin Proc. 2011 Nov;86(11):1113-23
pubmed: 22033257
Pharmacoepidemiol Drug Saf. 2003 Mar;12(2):113-20
pubmed: 12642974
Arch Intern Med. 2003 Jul 28;163(14):1667-72
pubmed: 12885681
Pediatr Ann. 1998 Dec;27(12):790-5
pubmed: 9866136
Br J Gen Pract. 2013 Jul;63(612):e429-36
pubmed: 23834879